MA26528A1 - DERIVES HYDROXY SUBSTITUE DE 2-ALKYLIDENE HYDROXYCUMARANONES A ACTIVITE uPA-uPAR ANTAGONISTE COMME AGENT ANTITUMORAL ET/OU ANTIMETASTATIQUE. - Google Patents

DERIVES HYDROXY SUBSTITUE DE 2-ALKYLIDENE HYDROXYCUMARANONES A ACTIVITE uPA-uPAR ANTAGONISTE COMME AGENT ANTITUMORAL ET/OU ANTIMETASTATIQUE.

Info

Publication number
MA26528A1
MA26528A1 MA25200A MA25200A MA26528A1 MA 26528 A1 MA26528 A1 MA 26528A1 MA 25200 A MA25200 A MA 25200A MA 25200 A MA25200 A MA 25200A MA 26528 A1 MA26528 A1 MA 26528A1
Authority
MA
Morocco
Prior art keywords
hydroxycumaranones
upa
alkylidene
antagonist
tumor
Prior art date
Application number
MA25200A
Other languages
English (en)
Inventor
De Cillis Gianpiero
Konig Bernhard
Di Domenico Roberto
Oliva Ambrogio
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26528A1 publication Critical patent/MA26528A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA25200A 1997-07-31 1998-07-31 DERIVES HYDROXY SUBSTITUE DE 2-ALKYLIDENE HYDROXYCUMARANONES A ACTIVITE uPA-uPAR ANTAGONISTE COMME AGENT ANTITUMORAL ET/OU ANTIMETASTATIQUE. MA26528A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97113190 1997-07-31
EP98106946 1998-04-16

Publications (1)

Publication Number Publication Date
MA26528A1 true MA26528A1 (fr) 2004-12-20

Family

ID=26145681

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25200A MA26528A1 (fr) 1997-07-31 1998-07-31 DERIVES HYDROXY SUBSTITUE DE 2-ALKYLIDENE HYDROXYCUMARANONES A ACTIVITE uPA-uPAR ANTAGONISTE COMME AGENT ANTITUMORAL ET/OU ANTIMETASTATIQUE.

Country Status (21)

Country Link
US (1) US6200989B1 (fr)
EP (1) EP1012147B1 (fr)
JP (1) JP3241711B2 (fr)
KR (1) KR100343067B1 (fr)
AR (1) AR013374A1 (fr)
AT (1) ATE308535T1 (fr)
AU (1) AU745839B2 (fr)
BR (1) BR9811589A (fr)
CA (1) CA2296476A1 (fr)
DE (1) DE69832184D1 (fr)
HR (1) HRP20000031A2 (fr)
HU (1) HUP0004221A2 (fr)
ID (1) ID24525A (fr)
IL (1) IL134193A0 (fr)
MA (1) MA26528A1 (fr)
NO (1) NO20000366D0 (fr)
PE (1) PE106099A1 (fr)
PL (1) PL338614A1 (fr)
TR (1) TR200000272T2 (fr)
UY (1) UY25114A1 (fr)
WO (1) WO1999006387A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736869B2 (en) * 1999-01-30 2001-08-02 Roche Diagnostics Gmbh O-substituted hydroxycoumaranone derivatives as antitumor and antimetastatic agents
AU2002362030A1 (en) * 2001-11-27 2003-06-10 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
WO2003051347A1 (fr) * 2001-12-19 2003-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Utilisation d'antagonistes de recepteurs d'urokinase afin de moduler les blessures de reperfusion ischemique
WO2004076444A2 (fr) * 2003-02-25 2004-09-10 F. Hoffmann-La Roche Ag Nouveaux derives d'hydroxycoumaranone utilises en tant qu'agents antitumoraux et antimetastatiques a activite biologique amelioree dans des dosages cellulaires et a stabilite amelioree
WO2008050857A1 (fr) * 2006-10-27 2008-05-02 The University Of Tokyo Composé amide ou un sel de celui-ci, et inhibiteur de formation de biofilm, agent d'élimination de biofilm et bactéricide, chacun utilisant le composé amide ou un sel de celui-ci
US8258307B2 (en) 2006-11-07 2012-09-04 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
EP4092013A1 (fr) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions et procédés pour augmenter l'efficacité du métabolisme cardiaque
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
US11166942B2 (en) * 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
JP6611029B1 (ja) * 2018-11-05 2019-11-27 プキョン ナショナル ユニバーシティ インダストリ ユニバーシティ コーポレーション ファウンデーションPukyong National University Industry−University Cooperation Foundation 高周波超音波多焦点変換器、その製造装置、および製造方法
EP3976101A4 (fr) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. Méthodes de traitement de la fibrose faisant appel à des composés favorisant l'oxydation du glucose
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2901336A1 (de) * 1979-01-15 1980-07-24 Boehringer Mannheim Gmbh Neue arylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3209271A1 (de) 1982-03-13 1983-09-15 Boehringer Mannheim Gmbh, 6800 Mannheim Bicyclische phenolether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
WO1986001212A1 (fr) * 1984-08-13 1986-02-27 Biotechnology Australia Pty. Ltd. Minactivin
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands

Also Published As

Publication number Publication date
HUP0004221A2 (hu) 2001-04-28
WO1999006387A3 (fr) 1999-04-22
TR200000272T2 (tr) 2000-09-21
US6200989B1 (en) 2001-03-13
JP2001512113A (ja) 2001-08-21
NO20000366L (no) 2000-01-25
CA2296476A1 (fr) 1999-02-11
KR100343067B1 (ko) 2002-07-03
DE69832184D1 (de) 2005-12-08
ID24525A (id) 2000-07-20
WO1999006387A2 (fr) 1999-02-11
UY25114A1 (es) 2001-01-31
EP1012147A2 (fr) 2000-06-28
AU9155998A (en) 1999-02-22
PL338614A1 (en) 2000-11-06
KR20010022362A (ko) 2001-03-15
ATE308535T1 (de) 2005-11-15
JP3241711B2 (ja) 2001-12-25
BR9811589A (pt) 2000-09-19
HRP20000031A2 (en) 2000-10-31
EP1012147B1 (fr) 2005-11-02
AR013374A1 (es) 2000-12-27
NO20000366D0 (no) 2000-01-25
AU745839B2 (en) 2002-04-11
PE106099A1 (es) 1999-11-11
IL134193A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
PT946542E (pt) Derivados de indano ou de di-hidroindol
DE69721347D1 (de) Sprachaktivitätserkennung
NO973756D0 (no) Deteksjon av stemmeaktivitet
DE69716266D1 (de) Sprachaktivitätsdetektor
PT888359E (pt) Derivados de pirimidin-4-ona como pesticida
BR9611820A (pt) Derivados de quinolina
NO990918D0 (no) Ringformet kateter
GR3036420T3 (en) Novel benzimidazole derivatives having cgmp-phosphodisterase inhibiting activity
HUP9702242A3 (en) Inozitol-glykanes of inzulin-like activity
EP0891347A4 (fr) Derives triterpenes possedant une activite immunosuppressive
PT1025114E (pt) Derivados de eritromicina-cetolido 6-o-substituido 3'-n-modificados possuindo actividade antibacteriana
PT910944E (pt) Doseador de racoes
EP0920622A4 (fr) Detection de microbacteries
ATA38796A (de) Möbelbeschlagteil
MA26440A1 (fr) Derives de n-benzylazolium
BR9607535A (pt) Arabinofuranodidase de aspergillus
ZA975366B (en) Preparation of substituted 3-aryl-5-haloalkyl-pyrazoles having herbicidal activity.
DE59602693D1 (de) Lenk- oder Bockrolle
PT796843E (pt) Derivados de 1,25-di-hidroxi-16,22,23-trisde-hidro-colecalciferol
DE69705281D1 (de) Aschenbecher
FR2731245B1 (fr) Plancher de passerelle
KR970053464U (ko) 휴지걸이
AT3511U3 (de) Briefkasten oder briefkastenanlage
ES1033459Y (es) Criolla de adorno.
UA25779A (uk) Спосіб діагhостики раhhіх порушеhь фуhкціоhальhої активhості печіhки